ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,632.33
1.05%
Dow Jones
41,488.19
1.65%
Gold vs US Dollar
2,986.65
0.00%
Brent Oil
70.285
0.00%
Bitcoin
84,091.74
0.16%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Salarius Pharmaceuticals Inc (SLRX)

  7. Salarius Pharmaceuticals Inc (SLRX) News

Salarius Pharmaceuticals (SLRX)

Salarius Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SLRX
DateTimeSourceHeadlineSymbolCompany
11/03/202510:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
11/03/202510:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
03/02/202513:00GlobeNewswire Inc.Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic CancersNASDAQ:SLRXSalarius Pharmaceuticals Inc
21/01/202513:01Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:SLRXSalarius Pharmaceuticals Inc
17/01/202522:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
13/01/202513:36Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
13/01/202513:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
13/01/202513:00GlobeNewswire Inc.Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger AgreementNASDAQ:SLRXSalarius Pharmaceuticals Inc
30/12/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SLRXSalarius Pharmaceuticals Inc
27/12/202421:35Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SLRXSalarius Pharmaceuticals Inc
23/12/202417:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
16/12/202411:12Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:SLRXSalarius Pharmaceuticals Inc
01/11/202421:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SLRXSalarius Pharmaceuticals Inc
01/11/202421:04Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SLRXSalarius Pharmaceuticals Inc
27/09/202420:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
15/08/202420:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
14/08/202420:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
09/08/202421:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
09/08/202421:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
25/07/202421:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
25/07/202421:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
22/07/202421:25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
19/07/202421:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
11/07/202412:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
17/06/202412:11Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
17/06/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
17/06/202412:00GlobeNewswire Inc.Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual MeetingNASDAQ:SLRXSalarius Pharmaceuticals Inc
14/06/202420:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
12/06/202412:00GlobeNewswire Inc.Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock SplitNASDAQ:SLRXSalarius Pharmaceuticals Inc
13/05/202420:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SLRX

Your Recent History

LSE
SBTX
Skinbiotherapeutics
LSE
VAST
Vast Resources
LSE
AAZ
Anglo Asian Mining
LSE
AGL
Angle
LSE
SRSP
Sirius Petroleum
LSE
ITV
Itv
LSE
GKP
Gulf Keystone Petroleum
LSE
GOLD
LSE
SYME
Supply@me Capital
LSE
THG
Thg
LSE
MIN
Minoan
LSE
BARC
Barclays
LSE
AXL
Arrow Exploration
LSE
WG.
Wood Group (john)
LSE
NFDS
Northern Foods
LSE
PHE
Powerhouse Energy
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads